Page last updated: 2024-11-05

lanthanum

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Lanthanum is a soft, silvery-white metallic chemical element with the symbol La and atomic number 57. It is a rare earth element, meaning it is found in low concentrations in the Earth's crust and is difficult to extract. Lanthanum is the most reactive of all the rare earth elements and reacts readily with air and water to form a protective oxide layer. It is a key component of mischmetal, an alloy used in lighter flints, and is used in various applications including high-intensity lighting, glass polishing, and catalytic converters.'

Cross-References

ID SourceID
PubMed CID23926
CHEBI ID33336
CHEBI ID37317
MeSH IDM0012214

Synonyms (72)

Synonym
LA ,
lanthanum ,
lanthane
7439-91-0
lantano
CHEBI:33336 ,
57la
lanthanum atom
lanthan
CHEBI:37317
lanthanum(ii) cation
la(2+)
lanthanum(2+)
lanthanum(2+) ion
lanthanum, pieces
lanthanum ion(2 )
lanthanum, ion (la2 )
LA2 ,
6i3k30563s ,
ec 231-099-0
unii-6i3k30563s
einecs 231-099-0
lanthanum [mi]
lanthanum [vandf]
FZLIPJUXYLNCLC-UHFFFAOYSA-N
DTXSID0064676 ,
AKOS024438058
lanthanum pieces
lanthanum rod, 12.7mm (0.5in) dia
lanthanum rod, 6.35mm (0.25in) dia
lanthanum foil, 0.1mm (0.004in) thick
lanthanum foil, 1.0mm (0.04in) thick
lanthanum powder, -200 mesh
mfcd00011066
lanthanum powder, 3n
lanthanum ingot
lanthanum foil, 3n
lanthanum chips, 2n6
lanthanum, foil, 100x100mm, thickness 0.125mm, as rolled, 99%
lanthanum, foil, not light tested, 100x100mm, thickness 0.025mm, as rolled, 99%
lanthanum, rod, 50mm, diameter 6.35mm, cast, 99%
lanthanum, foil, 29x33mm, thickness 0.5mm, as rolled, 99%
lanthanum, foil, 100x100mm, thickness 0.1mm, as rolled, 99%
lanthanum, foil, 50x50mm, thickness 0.1mm, as rolled, 99%
lanthanum, rod, 100mm, diameter 6.35mm, cast, 99%
lanthanum, foil, 35x47mm, thickness 0.5mm, as rolled, 99%
lanthanum, lump, 25 mm max. lump size, weight 100 g, purity 99%
lanthanum, foil, 50x50mm, thickness 0.125mm, as rolled, 99%
lanthanum, foil, 25x25mm, thickness 0.125mm, as rolled, 99%
lanthanum, foil, 25x25mm, thickness 0.1mm, as rolled, 99%
lanthanum, lump, 25 mm max. lump size, weight 50 g, purity 99%
lanthanum, foil, not light tested, 50x50mm, thickness 0.025mm, as rolled, 99%
lanthanum, powder, 400 max. part. size (micron), weight 50 g, purity 99.9%
lanthanum, powder, 400 max. part. size (micron), weight 25 g, purity 99.9%
lanthanum, lump, 25 mm max. lump size, weight 20 g, purity 99%
lanthanum, foil, not light tested, 25x25mm, thickness 0.025mm, as rolled, 99%
Q26841224
Q27117102
lanthanum sputtering target, 50.8mm dia x 3.18mm thick
AMY22284
lanthanum, (ingot)
lanthanum standard: la @ 1000 microg/ml in 5% hno3
lanthanum standard: la @ 5000 microg/g in hydrocarbon oil
lanthanum standard: la @ 10000 microg/ml in 5% hno3
lanthanum nitrate releasing agent: 1% la (from oxide) in 5% hno3
lanthanum - la @ 1000 microg/g in hydrocarbon oil
lanthanum chloride releasing agent: 1% la (from oxide) in 2% hcl
lanthanum metallicum
dtxcid8047638
contains 1% la (from lanthanum oxide) in 2% hcl
lanthanum - la @ 1000 microg/ml in 5% hno3
contains 1% la (from lanthanum oxide) in 5% hno3

Research Excerpts

Overview

Lanthanum (La) is a natural rare-earth element that can damage the central nervous system and impair learning and memory. Lanthanum carbonate is a commonly used phosphate binder for patients with CRF and hyperphosphatemia.

ExcerptReferenceRelevance
"Lanthanum (La) is a natural rare-earth element that can damage the central nervous system and impair learning and memory. "( Lanthanum Chloride Induces Axon Abnormality Through LKB1-MARK2 and LKB1-STK25-GM130 Signaling Pathways.
Jin, C; Liu, J; Lu, X; Mao, H; Song, Z; Sun, W; Wu, S; Yang, J, 2023
)
3.8
"Lanthanum carbonate is a commonly used phosphate binder for patients with CRF and hyperphosphatemia, but has adverse effects if patients are not monitored."( A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.
Chang, X; Li, M; Shang, S; Xu, W; Yu, M; Zhou, Q, 2023
)
1.86
"Lanthanum is a rare-earth element that has been used in various fields including medicine, agriculture and industry. "( Postweaning exposure to lanthanum alters neurological behavior during early adulthood in rats.
Jia, X; Jiao, B; Liang, C; Liu, Z; Sang, Y; Song, Y; Xiao, X; Yang, H; Yong, L, 2021
)
2.37
"Lanthanum (La) is a rare earth element that can influence plant growth and development. "( Lanthanum (La) improves growth, yield formation and 2-acetyl-1-pyrroline biosynthesis in aromatic rice (Oryza sativa L.).
Chen, Y; He, L; Luo, H; Tang, X, 2021
)
3.51
"Lanthanum is a rare earth element (REE) which has been extensively studied due to its wide application in numerous fields with a potential accumulation in the environment. "( The rare earth element (REE) lanthanum (La) induces hormesis in plants.
Agathokleous, E; Calabrese, EJ; Kitao, M, 2018
)
2.21
"Lanthanum carbonate is an effective, calcium-free phosphate binder, but little is known about the long-term impact on mineral metabolism, nutritional status and survival."( Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate.
Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Wada, T, 2019
)
1.46
"Lanthanum is an effective phosphate binder, and long-term effects of tissue deposition seem clinically irrelevant."( Current and potential treatment options for hyperphosphatemia.
Carfagna, F; Del Vecchio, L; Locatelli, F; Pontoriero, G, 2018
)
1.2
"Lanthanum is an important rare earth element and has many applications in modern electronics and catalyst manufacturing. "( Biotransformation of lanthanum by Aspergillus niger.
Csetenyi, L; Gadd, GM; Kang, X, 2019
)
2.28
"Lanthanum carbonate is a phosphate binder that is used to reduce serum phosphate levels in patients with end-stage renal disease (ESRD). "( Lanthanum phosphate binder-induced iron deficiency anaemia.
Awad, C; Gilkison, K; Shaw, E, 2019
)
3.4
"Lanthanum carbonate is a non-calcium phosphorus chelator used in the treatment of hyperphosphatemia associated with chronic renal disease. "( [Deposits of lanthanum in the gastric mucosa of a patient with chronic kidney disease].
António da Conceiçao, A; Castellano Megías, VM; Chiva Robles, MT; Porres Cubero, JC; Saus Sarrias, C,
)
1.94
"Lanthanum is a rare earth element which can have adverse effects on the central nervous system (CNS). "( Lanthanum chloride induces neuron damage by activating the nuclear factor-kappa B signaling pathway in activated microglia.
Cai, Y; Huang, L; Jin, C; Lu, X; Lu, Y; Wang, J; Wu, S; Yan, L; Yang, J; Yu, M, 2019
)
3.4
"Lanthanum carbonate is a powerful phosphate binder that has shown efficacy and safety in clinical trials for hyperphosphataemia management, although there are few data in regular clinical practice. "( REFOS study: efficacy and safety of lanthanum carbonate in clinical practice in Spain.
Cannata-Andía, J; González, MT; González-Parra, E; Torregrosa, JV, 2014
)
2.12
"Lanthanum carbonate is a non-calcium phosphate binder that is effective for the treatment of hyperphosphatemia. "( Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia.
Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Suzuki, H, 2015
)
2.17
"Lanthanum carbonate is a popular chemical which is administered for patients with end-stage kidney disease to reduce the absorption of phosphate, and lanthanum deposition in the gastroduodenal mucosa has recently been reported. "( Gastric mucosal status susceptible to lanthanum deposition in patients treated with dialysis and lanthanum carbonate.
Ban, S; Imada, H; Kubota, K; Ohshima, S; Satoh, H; Suzuki, S; Ueda, Y, 2017
)
2.17
"Lanthanum is an element belonging to the group called rare earths. "( [Lanthanum carbonate in clinical practice].
Torregrosa Prats, V, 2008
)
2.7
"Lanthanum (La) is a rare earth element that is widely used for industrial, medical and agricultural purposes. "( The neuroprotective role of L-cysteine towards the effects of short-term exposure to lanthanum on the adult rat brain antioxidant status and the activities of acetylcholinesterase, (Na+,K+)- and Mg2+-ATPase.
Al-Humadi, H; Anifantaki, F; Gkrouzman, E; Liapi, C; Mellios, Z; Skandali, N; Theocharis, S; Tsakiris, S; Zarros, A, 2009
)
2.02
"Lanthanum (La) is a rare-earth metal with applications in agriculture, industry, and medicine. "( Effects of lanthanum on human lymphocytes viability and DNA strand break.
Cabral-Neto, JB; de Almeida, CE; de Oliveira, LG; de Oliveira, MS; Paiva, AV; Yunes, SN, 2009
)
2.19
"Lanthanum carbonate is a new phosphate binder that is poorly absorbed from the gastrointestinal tract and eliminated largely by the liver. "( Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure.
Behets, GJ; Bervoets, AR; Blust, R; D'Haese, PC; Damment, SJ; Dauwe, S; De Broe, ME; Mubiana, VK; Roels, F; Schryvers, D; Verberckmoes, SC; Yang, Z, 2009
)
2.04
"Lanthanum (La) is a rare-earth element in transition Group III b of the periodic table. "( [Pharmacodynamic and pharmacokinetic profile of lanthanum carbonate].
Joki, N, 2009
)
2.05
"Lanthanum carbonate is a newer phosphate binder with phosphate binding activity similar to aluminum salts making this agent a compelling alternative; however, more data are needed to evaluate long-term safety and effects on cardiovascular end points."( Therapeutic use of the phosphate binder lanthanum carbonate.
Barton Pai, A; Conner, TA; McQuade, CR, 2009
)
1.34
"Lanthanum is a third-generation, non-calcium and non-aluminium-based phosphate binder indicated for the treatment of hyperphosphatemia in stage 5 chronic kidney disease. "( [Why does a patient on hemodialysis have radiopaque material in his abdomen?].
Aucella, F; Marinelli, T; Paoletti, D; Vigilante, M; Vocino, V,
)
1.57
"Lanthanum carbonate is a non-calcium phosphate binder used to control hyperphosphataemia in patients with chronic kidney disease who are undergoing dialysis. "( Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact?
Cox, AG; Damment, SJ; Secker, R, 2009
)
2.02
"Lanthanum carbonate is a non-calcium-based phosphate binder for hyperphosphatemia in patients with chronic kidney disease (CKD). "( One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu, T, 2010
)
2.09
"Lanthanum carbonate is a novel non-calcium, non-aluminum phosphate-binding agent, and has approved for clinical use in patients on hemodialysis in Japan on March in 2009."( [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Negi, S; Shigematsu, T, 2010
)
1.32
"Lanthanum carbonate is a non-aluminum, non-calcium phosphate binder. "( Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients.
Shigematsu, T, 2010
)
2.09
"Lanthanum carbonate is a calcium-free phosphate binder indicated in patients with chronic kidney disease."( [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
Laville, M, 2011
)
1.4
"Lanthanum therapy is an efficient therapy of hyperphosphoremia by chelating phosphore in the digestive tract. "( Radio-opaque fecal impaction and pseudo-occlusion in a dialyzed patient taking lanthanum carbonate.
Chantrel, F; Faller, B; Klein, A; Muller, C; Muller, S; Sissoko, A, 2012
)
2.05
"Lanthanum (La) is an important rare earth element in the ecological environment of plant. "( Interaction between La(III) and proteins on the plasma membrane of horseradish.
Chu, YX; Huang, XH; Lv, XF; Yang, GM; Zhou, Q, 2012
)
1.82
"Lanthanum carbonate is a non-calcium chelator not associated with these issues."( Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
Ardini, M; Corbani, V; Falqui, V; Londrino, F; Rombolà, G; Zattera, T,
)
2.3
"Lanthanum carbonate is an effective phosphate binder that can control serum phosphate and Ca×P product in CAPD patients with hyperphosphatemia. "( Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis.
Ito, H; Izumi, K; Katoh, S; Nagaya, M; Oda, H; Ohashi, H; Ohno, M; Okada, M; Yokoyama, H,
)
3.02
"Lanthanum carbonate is an intestinal phosphate binder that is orally administered to patients on dialysis to treat hyperphosphatemia."( Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats.
D'Haese, PC; Hoppe, B; Robijn, S; Verhulst, A; Vervaet, BA, 2013
)
2.55
"Lanthanum carbonate is a promising agent for the future prevention/treatment of secondary hyperoxaluria."( Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats.
D'Haese, PC; Hoppe, B; Robijn, S; Verhulst, A; Vervaet, BA, 2013
)
3.28
"Lanthanum carbonate is an efficacious and well-tolerated oral phosphate binder with a mild AE profile in hemodialysis and CAPD patients. "( Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.
Chen, JH; Chen, XM; Ding, GH; Fan, YP; Liu, ZH; Mei, CL; Ni, ZH; Wang, LN; Wang, M; Xu, J; Yu, XQ; Yuan, FH; Zhang, AP; Zhang, YX, 2013
)
3.28
"Lanthanum carbonate is a novel, non-calcium, non-aluminum phosphate binder under evaluation for the treatment of hyperphosphatemia in end-stage renal disease (ESRD) patients receiving either hemodialysis or continuous ambulatory peritoneal dialysis."( Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Finn, WF; Joy, MS, 2003
)
1.97
"Lanthanum carbonate is an effective and well-tolerated agent for the treatment of hyperphosphatemia in patients with ESRD."( Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Finn, WF; Joy, MS, 2003
)
1.97
"Lanthanum carbonate is a novel, non-aluminium, non-calcium phosphate binding agent that forms a water-insoluble compound, lanthanum phosphate, in the gut. "( Lanthanum carbonate.
Scott, LJ; Swainston Harrison, T, 2004
)
3.21
"Lanthanum carbonate is a highly effective phosphate binder with significant potential as a treatment for hyperphosphatemia in patients with end-stage renal disease (ESRD). "( Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
Finn, WF; Hladik, G; Joy, MS, 2004
)
2.08
"Lanthanum carbonate is an effective and well-tolerated agent for the short-term treatment of hyperphosphatemia in patients with ESRD."( Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
Finn, WF; Hladik, G; Joy, MS, 2004
)
2.08
"Lanthanum carbonate is an effective phosphate binder able to control serum phosphate and calcium x phosphate product."( Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
Al-Baaj, F; Hutchison, AJ; Speake, M, 2005
)
2.05
"Lanthanum carbonate is a non-calcium, non-aluminium phosphate-binding agent."( Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
Albaaj, F; Hutchison, AJ, 2005
)
2.49
"Lanthanum carbonate is an effective phosphate-binding agent without significant risk of hypercalcemia or worsening metabolic acidosis. "( Lanthanum carbonate.
Brooks, T; Candiani, C; Hudson, JQ; Joy, MS; Kshirsagar, A, 2006
)
3.22
"Lanthanum carbonate is a phosphate binder with demonstrated efficacy, safety, and tolerability in clinical trials."( Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
Altmann, P; Barnett, ME; Finn, WF, 2007
)
1.28
"Lanthanum carbonate is an alternative nonaluminium, noncalcium phosphate binder."( Lanthanum carbonate.
Freemont, AJ, 2006
)
2.5
"Lanthanum carbonate is a non-calcium-based oral phosphate binder for the control of hyperphosphataemia in patients with chronic kidney disease Stage 5. "( Systemic lanthanum is excreted in the bile of rats.
Damment, SJ; Pennick, M, 2007
)
2.2
"Lanthanum carbonate is a safe and effective binder with data demonstrating no toxic effects after continuous exposure up to 6 years."( Lanthanum carbonate--a first line phosphate binder?
de Freitas, D; Donne, RL; Hutchison, AJ,
)
2.3
"Lanthanum carbonate is a newer aluminum-free, calcium-free phosphate-binding agent."( Lanthanum carbonate as a first-line phosphate binder: the "cons".
Drüeke, TB,
)
2.3
"Lanthanum carbonate is a potent and selective phosphate binder that retains high affinity for phosphate over a wide pH range, does not bind bile acids or contribute to metabolic acidosis, and has the potential to reduce pill burden and increase patient compliance compared with other phosphate binders."( A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague, SM, 2007
)
1.27
"Lanthanum carbonate is a new nonaluminium, noncalcium phosphate binder. "( [Radiographic characteristics of lanthanum carbonate absorption].
Daem, AO; Lefèbvre, D; Lemaitre, V; Vrigneaud, L, 2008
)
2.07
"Lanthanum carbonate is a novel non-calcium-based phosphate binder for the treatment of chronic kidney disease."( Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
Shigematsu, T, 2008
)
2.51
"Lanthanum (La) is an extracellular tracer, which stains the interstitial space and the cell surface. "( Influence of incubation time and rinsing buffer on the distribution of the tracer lanthanum in canine heart muscle.
Fehrenbach, H; Richter, J; Schmiedl, A, 1998
)
1.97
"Lanthanum is a well known cellular calcium entry modifier."( Cellular calcium homeostasis changes in lymphoma-induction by ATP iron complex.
Anghileri, LJ; Domingo, JL; Mayayo, E; Thouvenot, P,
)
0.85
"Lanthanum (La+++) is a well-known Ca++ antagonist in a number of biological systems. "( Lanthanum: inhibition of ACTH-stimulated cyclic AMP and corticosterone synthesis in isolated rat adrenocortical cells.
Bedigian, E; Haksar, A; Maudsley, DV; Péron, FG, 1976
)
3.14
"Lanthanum is known to be a marker of extracellular spaces. "( Intracellular and intramitochondrial binding of lanthanum in dark degenerating midgut cells of a collembolan (insect).
Humbert, W, 1978
)
1.96

Effects

Lanthanum carbonate has shown significant promise in clinical trials in ESRD patients. Lanthanum ion (La(3+)) has been reported to affect proliferation or apoptosis of different cells.

ExcerptReferenceRelevance
"Lanthanum has an extremely high affinity for phosphate, and the experiments were designed to examine the role of this anion as a receptor site for chlorhexidine in the oral cavity."( Effect of chlorhexidine and lanthanum on plaque formation.
Rölla, G; Wåler, SM, 1983
)
1.28
"Oxylanthanum carbonate has the lowest daily phosphate binder dose volume and the smallest volume required to bind 1 g of phosphate compared to all other commercially available phosphate binders. "( High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders.
Gupta, P; Jermasek, D; Reddy, G; Sprague, SM, 2023
)
1.8
"Lanthanum (La) have been used to improve agricultural yield and quality, but the effect of La application on Cd/Pb enrichment in leafy vegetables remains incomplete currently."( Foliar spraying of lanthanum activates endocytosis in lettuce (Lactuca sativa L.) root cells, increasing Cd and Pb accumulation and their bioaccessibility.
Dong, Z; Guo, T; He, D; Li, H; Li, J; Lin, X; Liu, Y; Wang, F; Zong, X, 2024
)
2.49
"Lanthanum carbonate has the potential to chelate to drugs with anionic groups and therapeutic co-administration with lanthanum carbonate may reduce the bioavailibility of drugs like tetracyclines, quinolones and levothyroxine."( Lanthanum Carbonate - A New Phosphate Binding Drug in Advanced Renal Failure.
Aaseth, J; Bjorke-Monsen, AL, 2018
)
2.64
"Lanthanum carbonate has no effect on soluble klotho and serum FGF-23 in late stage of CRF."( High phosphate feeding induced arterial medial calcification in uremic rats: roles of Lanthanum carbonate on protecting vasculature.
Akhtar, J; Chen, B; Wang, H; Wang, R; Yu, C; Zhang, H; Zhao, T, 2013
)
1.33
"Lanthanum carbonate has the same phosphorus depressant effect as the other phosphorus adsorbents, and is expected to decrease digestive symptom onset such as constipation in Japanese patients undergoing hemodialysis compared to sevelamar hydrochloride. "( Gastrointestinal symptoms after the substitution of sevelamer hydrochloride with lanthanum carbonate in Japanese patients undergoing hemodialysis.
Hayashi, H; Ichie, T; Sugiura, Y; Sugiyama, T; Suzuki, D, 2015
)
2.09
"Lanthanum has been chosen as representative of the rare earths while copper has been considered since it is by far the most used metal in electric and electronic equipment."( Recovery of valuable metals from electronic scraps by clays and organo-clays: Study on bi-ionic model solutions.
Cristiani, C; Dotelli, G; Gallo Stampino, P; Iannicelli-Zubiani, EM, 2017
)
1.18
"Lanthanum carbonate has shown significant promise in clinical trials in ESRD patients."( Safety of new phosphate binders for chronic renal failure.
Loghman-Adham, M, 2003
)
1.04
"Lanthanum carbonate has been shown to be a highly effective phosphate binder in pre-clinical studies."( Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
Al-Baaj, F; Hutchison, AJ; Speake, M, 2004
)
1.25
"Lanthanum carbonate has been shown in clinical studies of up to 3 years to be an effective, well-tolerated phosphate binder. "( Lanthanum carbonate: a new phosphate binder.
Behets, GJ; D'Haese, PC; De Broe, ME; Verberckmoes, SC, 2004
)
3.21
"Lanthanum carbonate has been proposed as a new phosphate binder."( Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
Behets, GJ; Bouillon, R; D'Haese, PC; Damment, SJ; Dams, G; De Broe, ME; Vercauteren, SR, 2004
)
1.34
"Lanthanum ion (La(3+)) has been reported to affect proliferation or apoptosis of different cells. "( La3+-promoted proliferation is interconnected with apoptosis in NIH 3T3 cells.
Ke, Y; Qian, ZM; Wang, K; Yang, X; Yu, S; Yuan, L, 2005
)
1.77
"Lanthanum carbonate has been shown to be a safe, effective phosphate-binding agent. "( Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.
Behets, GJ; Bervoets, AR; Cox, AG; D'Haese, PC; De Broe, ME; Denton, J; Oste, L; Salomé, M; Verberckmoes, SC, 2005
)
2.12
"Lanthanum carbonate has been recently approved as non-calcium-based therapy for phosphate reduction in patients with stage 5 CKD requiring dialysis. "( Lanthanum carbonate.
Brooks, T; Candiani, C; Hudson, JQ; Joy, MS; Kshirsagar, A, 2006
)
3.22
"Lanthanum carbonate has similar phosphate control to calcium-based binders with less incidence of hypercalcemia but long-term clinical studies are needed for testing long-term exposure."( Emerging drugs for hyperphosphatemia.
Bellinghieri, G; Santoro, D; Savica, V, 2007
)
1.06
"Lanthanum has been extensively used to evaluate the role of extracellular and membrane-bound calcium on several aspects of cell function. "( Effect of lanthanum on urinary acidification and sodium transport by the turtle and toad bladder.
Arruda, JA; Sabatini, S, 1984
)
2.11
"Lanthanum has an extremely high affinity for phosphate, and the experiments were designed to examine the role of this anion as a receptor site for chlorhexidine in the oral cavity."( Effect of chlorhexidine and lanthanum on plaque formation.
Rölla, G; Wåler, SM, 1983
)
1.28
"Lanthanum has been used as a tracer for the intercellular space and the surface coats in different epithelia including human epidermis, however, lanthanum compounds may or may not penetrate into skin specimes and reaction product may or may not be present in the intercellular space. "( [Disturbed distribution of surface glycoconjugates of the plasma cell membrane in psoriasis. Cytochemical detection using the alcianblue-lanthan-reaction (author's transl)].
Mahrle, G; Orfanos, CE; Runne, U, 1976
)
1.7
"Lanthanum (1.9 mM) has previously been shown to produce a massive increase in the frequency of spontaneous miniature junction potentials at the neuromuscular junctions of goldfish fin muscles. "( The effect of lanthanum on nerve terminals in goldfish muscle after paralysis with tetanus toxin.
Beaumont, MA; Mellanby, J; Thompson, PA, 1988
)
2.08
"Lanthanum has been used effectively in studies of calcium physiology in experiments of short duration. "( Calcium regulation of skeletal myogenesis: IV. A defined culture medium permissive for myotube formation and the use of the calcium antagonist lanthanum.
Kirby, AC; Przybylski, RJ; Szigeti, V, 1986
)
1.91
"Lanthanum has been employed because of its widespread use as an 'extracellular' marker and because its presence can be unequivocally demonstrated by X-ray microanalysis."( Ultrastructural and X-ray microanalytical studies of EGTA- and detergent-treated heart muscle.
Elder, HY; Miller, DJ; Smith, GL, 1985
)
0.99

Actions

Lanthanum (La) can inhibit the acidogenicity of dental plaque and La-containing hydroxyapatite (La-HA) possesses a series of attractive properties. Lanthanum could cause cognitive impairment in children and rodent animals.

ExcerptReferenceRelevance
"Lanthanum could cause cognitive impairment in children and rodent animals. "( Lanthanum Chloride Impairs the Blood-Brain Barrier Integrity by Reduction of Junctional Proteins and Upregulation of MMP-9 in Rats.
Cai, Y; Hu, X; Jin, C; Lu, X; Ma, H; Wu, J; Wu, S; Yang, J; Zhang, L, 2019
)
3.4
"Lanthanum (La) can cause central nervous system damage in rats and lead to learning and memory impairment, but the relevant mechanisms have not been fully elucidated. "( Lanthanum chloride induces autophagy in rat hippocampus through ROS-mediated JNK and AKT/mTOR signaling pathways.
Cai, Y; Gao, X; Han, Y; Jin, C; Li, Y; Liu, S; Lu, X; Wu, S; Yang, J; Yu, M, 2019
)
3.4
"Lanthanum (La) can inhibit the acidogenicity of dental plaque and La-containing hydroxyapatite (La-HA) possesses a series of attractive properties, in contrast to La-free HA."( Lanthanum-containing hydroxyapatite coating on ultrafine-grained titanium by micro-arc oxidation: a promising strategy to enhance overall performance of titanium.
Deng, Z; Liu, C; Liu, J; Ma, J; Wang, L; Zhang, D, 2014
)
2.57
"Lanthanum chloride can inhibit the proliferation and migration of cervical cancer cells, and induce apoptosis by down-regulating cyclinD1, A20, and MMP-9 expressions in vitro."( [Effects of lanthanum chloride on proliferation and migration of human cervical cancer cell line HeLa cells].
Chen, XP; Guo, F; Liu, SS; Lu, D; Miao, LF; Wang, Y; Xiong, QY, 2010
)
2.18
"Lanthanum can inhibit lipopolysaccharide induced NF-kappaB activation."( [Effects of lanthanum on inhibition of lipopolysaccharide induced NF-kappaB activation].
Guo, F; Li, GH; Lou, YL; Wang, Y; Xie, A, 2007
)
1.44
"Lanthanum caused an increase in Gm at all stages of development."( Different actions of calcium channel blocking agents on resting membrane conductance in developing skeletal muscle.
Dryden, WF; Thomson, CM, 1981
)
0.98
"Lanthanum ions also inhibit Ca2+ uptake and neurotransmitter release in synaptosomes, but no paralysis was observed after La2+ IP injection."( Effects of drugs on neurotransmitter release: experiments in vivo and in vitro.
Tapia, R, 1985
)
0.99

Treatment

Lanthanum treatment significantly decreased grip strength, hindlimb strength, and running time & distance in motor activity test. Pretreatment with lanthanum (20 microM) abolished the steady level produced by bradykinin but had little effect on the initial, transient rise in cytosolic calcium.

ExcerptReferenceRelevance
"Lanthanum treatment dose-dependently increased blood lanthanum concentration in dams and pups."( Effects of in utero exposure to lanthanum on neurological behavior in rat offspring.
Jia, X; Liang, C; Liu, D; Liu, Z; Song, Y; Xiao, X; Yang, H; Yong, L,
)
1.14
"Lanthanum treatment also significantly decreased grip strength, hindlimb strength, and running time & distance in motor activity test."( Postweaning exposure to lanthanum alters neurological behavior during early adulthood in rats.
Jia, X; Jiao, B; Liang, C; Liu, Z; Sang, Y; Song, Y; Xiao, X; Yang, H; Yong, L, 2021
)
1.65
"Lanthanum treatment caused a robust stimulation of bone formation with an activation of osteoblasts on the endosteal surface of femoral diaphysis, leading to an increase in cortical bone volume."( Lanthanum carbonate stimulates bone formation in a rat model of renal insufficiency with low bone turnover.
Fumoto, T; Ikeda, K; Ito, M, 2014
)
2.57
"Lanthanum-treated patients experienced a significant reduction in 24-h urinary phosphate excretion compared with baseline (64%; P<0.0001), but the difference compared with placebo did not reach significance (64% vs."( Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.
Epstein, M; Gutiérrez, OM; Isakova, T; Jüppner, H; Keating, LK; Smith, K; Wolf, M, 2011
)
1.09
"Lanthanum carbonate-treated patients continued taking their established maintenance dose ('continued-lanthanum group') and calcium carbonate-treated patients switched to lanthanum carbonate, 375-3,000 mg/day ('switch group')."( Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
Asmus, G; Backs, W; Hutchison, AJ; Jamar, R; Maes, B; Mohamed, E; Schmieder, R; Vanwalleghem, J; Vosskühler, A, 2006
)
1.32
"Lanthanum pretreatment prior to stimulation caused no significant change in baseline, peak or plateau calcium levels as compared to control."( Effects of capacitative calcium entry on agonist-induced calcium transients in A7r5 vascular smooth muscle cells.
Benoit, JN; Gardner, JD,
)
0.85
"In lanthanum-treated cells the volume was found to be proportional to the reciprocal of the osmotic pressure in the hypotonic range, but not in the control cells."( Hydrostatic pressure in epidermal cells is dependent on Ca-mediated contractions.
Bereiter-Hahn, J; Strohmeier, R, 1987
)
0.79
"Lanthanum treatment of gap junctions reveals an array of particles of 95 A diameter and 120 A separation lying in the plane of the junction."( Coexistence of gap and sseptate junctions in an invertebrate epithelium.
Hudspeth, AJ; Revel, JP, 1971
)
0.97
"Treatment with lanthanum is associated with improved survival in hemodialysis patients. "( Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate.
Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Wada, T, 2019
)
1.09
"Treatment with lanthanum was independently associated with a significant survival benefit in hemodialysis patients with inadequately controlled hyperphosphatemia. "( Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia.
Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Suzuki, H, 2015
)
1.08
"Treatment with lanthanum carbonate reduced hyperphosphataemia and secondary hyperparathyroidism in CRF animals (P < 0.05), and had little effect in NRF animals."( Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure.
Damment, S; Lorenzo, V; Rodriguez, M; Secker, R; Shen, V, 2011
)
1.01
"Treatment with lanthanum (La3+) after fixation in phosphate (PO4-3)-buffered glutaraldehyde results in the deposition of a cell surface material (CSM) primarily on the developing urodele amphibian neural axis. "( A scanning electron microscopic and x-ray microanalytic study of cell surface material during amphibian neurulation.
Moran, DJ; Rice, RW, 1977
)
0.61
"Pretreatment with lanthanum (20 microM) abolished the steady level produced by bradykinin but had little effect on the initial, transient rise in cytosolic calcium."( Bradykinin-induced increases in cytosolic calcium and ionic currents in cultured bovine aortic endothelial cells.
Colden-Stanfield, M; Eskin, SG; Kunze, DL; Navarro, LT; Ritchie, AK; Schilling, WP, 1987
)
0.6

Toxicity

Lanthanum was most toxic to Daphnia in soft tap water (TW) with an acute 48-h EC50 of 43 microg/l. Sevelamer hydrochloride and Lanthanum carbonate has been shown to be effective, safe and useful therapeutic tools for hyperphosphatemia.

ExcerptReferenceRelevance
" In order to evaluate possible toxic effects of scandium, chromium, lanthanum, samarium, europium, dysprosium, terbium, thulium, and ytterbium oxides, and barium sulfate upon growth, general development, reproduction, and lactation, mice were fed different levels of these compounds for three generations."( Studies of nutritional safety of some heavy metals in mice.
Gray, DH; Hutcheson, DP; Luckey, TD; Venugopal, B, 1975
)
0.49
", cell viability, lysosomal enzyme leakage, or changes in cell surface morphology, cadmium was more toxic to these cells than were the rare earth metals."( Cytotoxicity of the rare earth metals cerium, lanthanum, and neodymium in vitro: comparisons with cadmium in a pulmonary macrophage primary culture system.
Butenhoff, JL; Palmer, RJ; Stevens, JB, 1987
)
0.53
"We have established conditions in which soluble Al is toxic to the yeast Saccharomyces cerevisiae."( A1 toxicity in yeast. A role for Mg?
Gardner, RC; MacDiarmid, CW, 1996
)
0.29
" Lanthanum was most toxic to Daphnia in soft tap water (TW) with an acute 48-h EC50 of 43 microg/l compared with 1180 microg/l in ASTM hard water (ASTM)."( The acute and chronic toxicity of lanthanum to Daphnia carinata.
Barry, MJ; Meehan, BJ, 2000
)
1.5
" Serum levels of phosphorus, calcium and parathyroid hormone, and adverse events were monitored throughout the study."( Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
Finn, WF; Hladik, G; Joy, MS, 2004
)
0.63
" Adverse events were mainly gastrointestinal (e."( Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
Finn, WF; Hladik, G; Joy, MS, 2004
)
0.63
"In this study, the toxic effect of sanguinarine (SANG) on heart was studied with isolated cardiac muscle strip isolated from Wistar rat."( Induction of contracture and extracellular Ca2+ influx in cardiac muscle by sanguinarine: a study on cardiotoxicity of sanguinarine.
Cheng, HW; Cheng, YW; Hu, CM; Kang, JJ; Liao, JW, 2005
)
0.33
" Safety and tolerability were assessed by monitoring adverse events, laboratory parameters, and vital signs."( A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
Finn, WF; Joy, MS, 2005
)
0.56
"Lanthanum carbonate was well tolerated and was associated with few treatment-related adverse events."( A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
Finn, WF; Joy, MS, 2005
)
2
" When shoot La content exceeded a toxic value, plant growth and chlorophyll a/b decreased and peroxidase (POD) activity, cell membrane permeability, and content of proline in the leaf increased."( Phytotoxicity of lanthanum in rice in haplic acrisols and cambisols.
Cheng, HL; Chu, HY; Xie, ZB; Zeng, Q; Zhu, JG, 2006
)
0.67
" Safety assessments included adverse events (AEs), full laboratory parameters and blood profiles."( Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
Finn, WF, 2006
)
1.78
" Indeed, in clinical studies no toxic effects of lanthanum have been reported after up to four years of follow-up."( Lanthanum: a safe phosphate binder.
Behets, GJ; Bervoets, AR; D'Haese, PC; De Broe, ME; Persy, VP,
)
1.83
" Liver magnetic resonance imaging and microscopy did not reveal toxic changes due to La."( Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats.
Ben-Dov, IZ; Galitzer, H; Ilan, Y; Naveh-Many, T; Pappo, O; Silver, J; Sklair-Levy, M, 2007
)
1.78
" There were no new or unexpected adverse events (AEs), and no increase in the incidence of events with increasing treatment exposure."( Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.
Barnett, ME; Hutchison, AJ; Krause, R; Kwan, JT; Siami, GA, 2008
)
0.61
" Adverse events classified as "liver and biliary system events" were recorded."( Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.
Barnett, ME; Hutchison, AJ; Krause, R; Siami, GA, 2009
)
1.8
"In the four initial clinical trials, lanthanum carbonate was not associated with any adverse changes in transaminases or bilirubin."( Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.
Barnett, ME; Hutchison, AJ; Krause, R; Siami, GA, 2009
)
2.07
"There was no evidence of adverse effects of lanthanum carbonate on the liver in patients who received treatment for up to 6 years."( Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.
Barnett, ME; Hutchison, AJ; Krause, R; Siami, GA, 2009
)
2.06
"05), without any increase in the frequency or severity of drug-related adverse events such as vomiting, nausea, and stomach discomfort."( One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu, T, 2010
)
0.64
" The results may suggest adverse impacts in REE-exposed biota and warrant further studies of a more extended REE series."( Cytogenetic and developmental toxicity of cerium and lanthanum to sea urchin embryos.
Bustamante, P; D'Ambra, A; Guida, M; Oral, R; Pagano, G; Warnau, M, 2010
)
0.61
" FC combined with Cd(2+) counteracted the toxic effect of Cd(2+) on endogenous growth and significantly decreased Cd(2+) content (not the case for Cd(2+) at the highest concentration) in coleoptile segments."( Fusicoccin counteracts the toxic effect of cadmium on the growth of maize coleoptile segments.
Karcz, W; Kita, A; Kurtyka, R, 2011
)
0.37
" Only in phosphate poor environments a toxic effect was observed."( Phosphate starvation as an antimicrobial strategy: the controllable toxicity of lanthanum oxide nanoparticles.
Gerber, LC; Grass, RN; Luechinger, NA; Moser, N; Stark, WJ, 2012
)
0.61
" A few serious adverse events (AEs) involving the biliary system occurred during the LC treatment period, but they were not considered to be treatment-induced."( Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.
Kasai, S; Kinoshita, Y; Murata, Y; Sato, K, 2012
)
0.6
" LC treatment was compared to pretreatment (no or other phosphate binders) regarding laboratory parameters, adverse events and tablet burden."( Efficacy and safety of lanthanum carbonate in German patients on dialysis.
Dellanna, F; Reichel, H; Seibt, F, 2012
)
0.69
" The results indicate that thorium and cerium individually have no toxic effects on lymphocytes."( The role of chemical interactions between thorium, cerium, and lanthanum in lymphocyte toxicity.
Almeida, CE; Duarte, IM; Mattos, RC; Oliveira, MS; Paiva, AV; Sarcinelli, PN; Yunes, SN, 2014
)
0.64
" The incidence of all adverse events was similar between LC- and placebo-treated patients (OR = 1."( Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
Guo, H; Tang, S; Zhang, S; Zhang, X, 2013
)
0.7
" On the other hand Sevelamer hydrochloride and Lanthanum carbonate has been shown to be effective, safe and useful therapeutic tools for hyperphosphatemia."( Hyperphosphatemia and phosphate binders: effectiveness and safety.
Elisaf, MS; Kalaitzidis, RG, 2014
)
0.66
" Accumulation of LC in blood and bone was below toxic levels."( Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.
Fan, J; Li, Z; Wen, J; Zhang, C, 2013
)
0.7
" Current evidence does not show a higher rate of adverse effects for LC compared with other treatments, except for a higher incidence of vomiting."( Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.
Fan, J; Li, Z; Wen, J; Zhang, C, 2013
)
0.7
" Results included values of serum calcium, phosphorus, alkaline phosphatase, iPTH, hepatic enzymes and haemogram, as well as the daily-prescribed dose of lanthanum carbonate, the concomitant medication, treatment compliance and adverse events."( REFOS study: efficacy and safety of lanthanum carbonate in clinical practice in Spain.
Cannata-Andía, J; González, MT; González-Parra, E; Torregrosa, JV, 2014
)
0.88
" An in vitro cytotoxicity test, according to EN ISO 10993-5/12, with L929 and human osteoblastic cells identified no toxic effects on cell viability at physiological concentrations (at 50% dilutions and higher)."( Novel magnesium alloy Mg-2La caused no cytotoxic effects on cells in physiological conditions.
Eifler, R; Hegermann, J; Reifenrath, J; Seitz, JM; Waizy, H; Weizbauer, A; Werle, P; Willbold, E; Windhagen, H, 2014
)
0.4
" The algal growth inhibition assay confirmed absence of toxic effects of La2O3 NP on Chlorella sp."( Toxicity of lanthanum oxide (La2O3) nanoparticles in aquatic environments.
Balusamy, B; Ergen, SF; Taştan, BE; Tekinay, T; Uyar, T, 2015
)
0.8
" In particular, we consider its toxic effects on the skeletal system."( Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Iwatani, Y; Masumoto, AR; Mima, T; Moribata, MK; Nakashima, YM; Negi, S; Ohya, M; Shigematsu, T; Tatsuta, K; Yamanaka, S, 2015
)
0.7
" The most common adverse effects are mild/moderate nausea, diarrhoea and flatulence."( Lanthanum carbonate: safety data after 10 years.
Copley, JB; Garafola, S; Hutchison, AJ; Wilson, RJ, 2016
)
1.88
" Toxic effects of REEs on humans have been extensively studied, but their toxic effects and binding targets in cells are not understood."( Toxic effects of environmental rare earth elements on delayed outward potassium channels and their mechanisms from a microscopic perspective.
Cheng, M; Du, C; He, J; Huang, X; Wang, L; Wei, H; Xia, A; Yang, Q; Zhou, Q, 2017
)
0.46
"The present study was undertaken to evaluate the subchronic toxicity of lanthanum and to determine the no observed adverse effect level (NOAEL), which is a critical factor in the establishment of an acceptable dietary intake (ADI)."( Subchronic Oral Toxicity Evaluation of Lanthanum: A 90-day, Repeated Dose Study in Rats.
Fang, HQ; Fang, J; Jia, XD; Li, CX; Peng, SQ; Wang, YM; Yu, Z; Zhi, Y, 2018
)
0.98
" Soil samples turned out to be less toxic compared to the solutions probably due to the decreased availability of REEs."( Toxicity assay of lanthanum and cerium in solutions and soil.
Fastovets, I; Kotelnikova, A; Rogova, O; Stolbova, V; Volkov, DS, 2019
)
0.85
" Toxic effects of mixtures were predicted using the reference model of Concentration Addition (CA), Ternary model, and Ternary-Plus model."( Model-based rationalization of mixture toxicity and accumulation in Triticum aestivum upon concurrent exposure to yttrium, lanthanum, and cerium.
Gong, B; He, E; Huang, X; Li, M; Qiu, H; Qiu, R; Ruan, J; Tang, Y; Van Gestel, CAM; Xiao, X, 2020
)
0.77
" Both La and Ce caused adverse effect to wheat, but the presence of Ca and NTA alleviated their toxicity."( Coherent toxicity prediction framework for deciphering the joint effects of rare earth metals (La and Ce) under varied levels of calcium and NTA.
Cao, X; He, E; Li, J; Qiu, H; Romero-Freire, A; Zhao, L, 2020
)
0.56
" Meta-analysis was performed to evaluate the serum biochemical parameters, adverse events, and patient-level outcomes of LC, non-LC PBs, and sevelamer for hyperphosphatemia in patients with CKD."( Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
Liu, A; Xu, G; Zhao, L, 2021
)
0.92
" Uranium is known to be toxic to plants and its uptake and toxicity can be influenced by multiple factors such as pH and the presence of different ions."( Calcium affects uranium responses in Arabidopsis thaliana: From distribution to toxicity.
Cuypers, A; Horemans, N; Mertens, A; Nauts, R; Saenen, E, 2022
)
0.72
" In this context, this aimed to evaluate the acute toxic effects of lanthanum (La), neodymium (Nd) and samarium (Sm), as both single and binary and ternary mixtures on the survival of the microcrustacean Daphnia similis."( Acute toxicity of single and combined rare earth element exposures towards Daphnia similis.
Correia, FV; Egler, SG; Giese, EC; Heidelmann, GP; Roldão, TM; Saggioro, EM; Santos, GO, 2023
)
1.15

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic investigations of lanthanum carbonate formed an important part of the stringent premarketing safety assessment process and have been influential in reassuring both regulators and physicians that the agent can be used safely and effectively in this vulnerable dialysis population."( Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.
Damment, SJ; Pennick, M, 2008
)
0.87
" In this review I would like to summarize the pharmacodynamic and pharmacokinetic profile of this new phosphate binder (La2[CO3]3) which will be registered in our country in the near future."( [Pharmacodynamic and pharmacokinetic profile of lanthanum carbonate].
Joki, N, 2009
)
0.61
"A Phase I, single-center, randomized, open-label, 2-period, crossover study to assess pharmacodynamic equivalence of the 2 formulations was conducted in healthy adults aged 18 to 55 years receiving a diet standardized for phosphate content."( Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects.
Hossack, S; Martin, P; Pierce, D; Robinson, A; Zhang, P, 2012
)
0.62
"82 mmol/d, confirming pharmacodynamic equivalence."( Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects.
Hossack, S; Martin, P; Pierce, D; Robinson, A; Zhang, P, 2012
)
0.62
"In this multiple-dose study, the oral powder and tablet formulations of LC were well tolerated and met the regulatory criteria for pharmacodynamic equivalence in these healthy volunteers."( Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects.
Hossack, S; Martin, P; Pierce, D; Robinson, A; Zhang, P, 2012
)
0.62

Compound-Compound Interactions

High-protein meals during dialysis combined with lanthanum carbonate are safe and increase serum albumin while controlling phosphorus. We evaluated the long-term efficacy and side effects of Lanthanum Carbonate used in combination with other phosphate binders in PD patients.

ExcerptReferenceRelevance
" We evaluated the long-term efficacy and side effects of lanthanum carbonate (LaC) used in combination with other phosphate binders in PD patients."( Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients.
Eriguchi, M; Kitazono, T; Nakano, T; Tanaka, S; Taniguchi, M; Tsuruya, K; Yamada, S; Yoshida, H, 2012
)
0.96
"Low dose LaC treatment used in combination with other phosphate binders improved serum phosphate control with tolerable gastrointestinal symptoms in PD patients."( Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients.
Eriguchi, M; Kitazono, T; Nakano, T; Tanaka, S; Taniguchi, M; Tsuruya, K; Yamada, S; Yoshida, H, 2012
)
0.72
"This short-term study assessed the efficacy and safety of calcium carbonate combined with calcitonin in the treatment of hypercalcemia in hemodialysis patients."( Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients.
Kong, XL; Li, WB; Wang, ZS; Wei, Y, 2014
)
0.4
" We hypothesized that, in hypoalbuminemic hemodialysis patients, provision of high-protein meals during hemodialysis combined with a potent phosphorus binder increases serum albumin without raising phosphorus levels."( Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial.
Benner, D; Bross, R; Jing, J; Kalantar-Zadeh, K; Koontz Parsons, T; Kopple, JD; Kovesdy, CP; Lee, ML; Mehrotra, R; Rhee, CM; St-Jules, DE; Tortorici, AR; You, AS, 2017
)
0.69
" Patients were randomly assigned to receive high-protein (50-55 g) meals during dialysis, providing 400-500 mg phosphorus, combined with lanthanum carbonate versus low-protein (<1 g) meals during dialysis, providing <20 mg phosphorus."( Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial.
Benner, D; Bross, R; Jing, J; Kalantar-Zadeh, K; Koontz Parsons, T; Kopple, JD; Kovesdy, CP; Lee, ML; Mehrotra, R; Rhee, CM; St-Jules, DE; Tortorici, AR; You, AS, 2017
)
0.9
"In hypoalbuminemic hemodialysis patients, high-protein meals during dialysis combined with lanthanum carbonate are safe and increase serum albumin while controlling phosphorus."( Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial.
Benner, D; Bross, R; Jing, J; Kalantar-Zadeh, K; Koontz Parsons, T; Kopple, JD; Kovesdy, CP; Lee, ML; Mehrotra, R; Rhee, CM; St-Jules, DE; Tortorici, AR; You, AS, 2017
)
0.92

Bioavailability

Lanthanum carbonate is used to prevent hyperphosphatemia in dialysis patients with chronic renal failure and generally recognized as poorly absorbed by the gastrointestinal tract. On a typical intake of lanthanum (3000 mg/day as lanthanums carbonate), the rate of absorption was calculated as 2. The oral bioavailability of Lanthanum Carbonate is less than 0.

ExcerptReferenceRelevance
" The bioavailability of lanthanum is extremely low."( Lanthanum: a safe phosphate binder.
Behets, GJ; Bervoets, AR; D'Haese, PC; De Broe, ME; Persy, VP,
)
1.88
" A randomized, open-label, parallel-group, phase I study was conducted to determine absolute bioavailability and investigate excretory routes for systemic lanthanum in healthy subjects."( Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate.
Damment, SJ; Dennis, K; Pennick, M, 2006
)
0.79
" It is poorly absorbed and does not require functioning kidneys to be removed from the body."( Lanthanum carbonate.
Freemont, AJ, 2006
)
1.78
"Lanthanum carbonate is a new phosphate binder that is poorly absorbed from the gastrointestinal tract and eliminated largely by the liver."( Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure.
Behets, GJ; Bervoets, AR; Blust, R; D'Haese, PC; Damment, SJ; Dauwe, S; De Broe, ME; Mubiana, VK; Roels, F; Schryvers, D; Verberckmoes, SC; Yang, Z, 2009
)
2.04
" Animal studies show that lanthanum has a very low bioavailability and absorbed lanthanum is primarily excreted in bile."( Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.
Barnett, ME; Hutchison, AJ; Krause, R; Siami, GA, 2009
)
2.1
" We investigated the effects of lanthanum carbonate and sevelamer carbonate on the bioavailability of oral calcitriol."( The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.
Hossack, S; Martin, P; Pierce, D; Poole, L; Robinson, A; Smyth, M; Van Heusen, H, 2011
)
0.92
" Electrolytically hydrided materials have the same high level magnetic properties as in high temperature gas-phase processed materials and offer an advantage of higher hydrogen absorption rate in the ferromagnetic state."( Electrolytic hydriding of LaFe(13-x)Si(x) alloys for energy efficient magnetic cooling.
Cohen, LF; Hannemann, U; Lyubina, J; Ryan, MP, 2012
)
0.38
" plant derived), and the protein-to-phosphorus ratio in the bioavailability of phosphorus from food."( Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
Adema, AY; de Borst, MH; Ter Wee, PM; Vervloet, MG, 2014
)
0.4
" We investigated the bioavailability of La from Phoslock in a controlled parallel groups experiment in which we measured the La in carapace, gills, ovaries, hepatopancreas and abdominal muscle after 0, 14 and 28 days of exposure to Phoslock."( Lanthanum from a modified clay used in eutrophication control is bioavailable to the marbled crayfish (Procambarus fallax f. virginalis).
Goitom, E; Lürling, M; Roessink, I; van Oosterhout, F, 2014
)
1.85
" It is poorly absorbed from the gastrointestinal tract, forms insoluble complexes within the lumen, and prevents the absorption of dietary phosphate."( Extensive lanthanum deposition in the gastric mucosa: the first histopathological report.
Kawaguchi, K; Kodama, R; Makino, M; Nagasawa, M; Nakamura, H; Shimojo, H, 2015
)
0.82
" Here, we assess the bioavailability of these anthropogenic microcontaminants in these rivers by analyzing the aragonitic shells of the freshwater bivalve Corbicula fluminea."( Rare earth elements in the aragonitic shell of freshwater mussel Corbicula fluminea and the bioavailability of anthropogenic lanthanum, samarium and gadolinium in river water.
Bau, M; Merschel, G, 2015
)
0.62
"Multiple contaminants can affect plant-microbial remediation processes because of their interactive effects on environmental behaviour, bioavailability and plant growth."( Effects of arbuscular mycorrhizal symbiosis on growth, nutrient and metal uptake by maize seedlings (Zea mays L.) grown in soils spiked with Lanthanum and Cadmium.
Chang, Q; Dang, ZH; Diao, FW; Guo, W; Pan, L; Wang, QF, 2018
)
0.68
" Our results highlighted the importance of considering mixture interactions and subsequent bioavailability in assessing the joint toxicity of REEs."( Phytotoxicity of individual and binary mixtures of rare earth elements (Y, La, and Ce) in relation to bioavailability.
Cao, X; Gong, B; He, E; Ji, J; Li, J; Qiu, H; Zhao, L, 2019
)
0.51
"Lanthanum carbonate is used to prevent hyperphosphatemia in dialysis patients with chronic renal failure and generally recognized as poorly absorbed by the gastrointestinal tract."( Early gastric cancer with lanthanum deposition mucosa by endoscopic submucosal dissection: a case report and literature review.
Fujimoto, D; Miyagi, A; Miyagi, J; Ogawa, H; Okushi, S; Takahashi, S; Tamura, U; Tanahashi, T, 2021
)
2.36
" A metal solution medium with (MS) and without EDTA and cyanocobalamin (MSq) as chelators was employed as the assay dilution water to assess REE bioavailability effects."( Acute toxicity of single and combined rare earth element exposures towards Daphnia similis.
Correia, FV; Egler, SG; Giese, EC; Heidelmann, GP; Roldão, TM; Saggioro, EM; Santos, GO, 2023
)
0.91
" However, they have poor bioavailability and many side effects."( Chitosan modified with lanthanum ions as implantable hydrogel for local delivery of bisphosphonates.
Buchwald, T; Domke, A; Jakubowski, M; Ratajczak, M; Sandomierski, M; Szczuka, J; Voelkel, A, 2023
)
1.22

Dosage Studied

Lanthanum carbonate (Fosrenol) has been used to treat chronic renal failure (CRF) The dosage is much higher than the daily intake of lanthanides. The dose-response curves suggest that there is more than one site with which lanthanum may interact.

ExcerptRelevanceReference
" Sdium nitroprusside causes a parallel shift of the dose-response curve of rat aorta to noradrenaline to the right and reduces the maximum response."( Mode of action of sodium nitroprusside on vascular smooth muscle.
Baron, GD; Kreye, VA; Lüth, JB; Schmidt-Gayk, H, 1975
)
0.25
" Stimulation of fluid secretion by 5-HT follows a definite dose-response curve, but there is no consistent relationship between the rate of enzyme secretion and the stimulating concentration of 5-HT."( The control of enzyme secretion from fly salivary glands.
Bay, CM, 1978
)
0.26
" Ca dose-response curves were obtained out on previously Ca-depleted La treated veins after stimulation by K, adrenaline or angiotensin."( Effects of adrenaline, angiotensin, potassium and calcium on lanthanum treated portal veins.
Savino, EA; Taquini, AC, 1977
)
0.5
" Dose-response curves to Ba2+ in SHR strips were displaced to the right as compared to NW rats."( Evidence for a visceral smooth muscle abnormality in Okamoto spontaneous hypertension.
Altman, J; Da Ponte, F; Worcel, M, 1977
)
0.26
" The dose-response curves suggest that there is more than one site with which lanthanum may interact."( Interaction between lanthanum and calcium in isolated guinea-pig heart.
Hwang, JC; Wong, PY; Yeung, CH, 1976
)
0.81
" An enhancing dose of La3+ shifted the dose-response curve for kainate to lower concentrations of agonist without changing the maximum evoked current, and a similar leftward shift of the quisqualate dose-response curve occurred at non-saturating concentrations of quisqualate."( Lanthanum actions on excitatory amino acid-gated currents and voltage-gated calcium currents in rat dorsal horn neurons.
MacDermott, AB; Reichling, DB, 1991
)
1.72
" H-7 produced a shift to the right of the dose-response curve for the PKC activator, 12-o-tetradecanoylphorbol-13-acetate (TPA) in the case of SHR aortas, while no such shift was noted in tissues from WKY."( Effects of H-7 (protein kinase inhibitor) and phorbol ester on aortic strips from spontaneously hypertensive rats.
Iwasaki, T; Miyata, S; Morita, S; Nagai, K; Shibata, R, 1990
)
0.28
" The La dose-response curves for H influx and for Ca efflux were similar [50% inhibitory concentration (IC50) = approximately 5 microM] in intact red blood cells."( Proton fluxes associated with the Ca pump in human red blood cells.
Milanick, MA, 1990
)
0.28
" Blocking the acetylcholine receptor shifted the dose-response relation for PGE-induced fusion to higher concentrations."( The control of chick myoblast fusion by ion channels operated by prostaglandins and acetylcholine.
Bevan, S; Entwistle, A; Warner, AE; Zalin, RJ, 1988
)
0.27
" In aorta strips depleted of Ca2+ by several applications of noradrenaline (10(-6) M), Sr2+ induced a dose-response contraction in a Ca2+-free solution."( Study of the strontium response in isolated rat aorta.
Anselmi, E; Barreda, A,
)
0.13
" Dose-response curves to alpha-MSH were compared in the presence of different calcium concentrations, and Schild regression plots were constructed."( The role of calcium in MSH stimulated melanosome dispersion.
Lucas, AM; Shuster, S; Thody, AJ,
)
0.13
" This hypothesis is used to generate dose-response curves describing the combined effects of epinephrine and theophylline, and these are compared with experimental data."( Mode of action of chronotropic agents in cardiac Purkinje fibers. Does epinephrine act by directly modifying the external surface charge?
Tsien, RW, 1974
)
0.25
" It seems unlikely that La3+ and L-glutamate were competing for a common binding site on the postsynaptic membrane since the apparent maximum of the dose-response curve for glutamate-induced depolarization was reduced in the presence of La3+."( Effect of lanthanum ions on neuromuscular transmission in insects.
Miyamoto, T; Washio, H, 1983
)
0.67
" PE log dose-response curves were shifted to the right in a non-parallel manner by 1 mM Mn2+ such that responses to lower PE concentrations were more inhibited."( Inhibition of alpha-receptor-induced Ca2+ release and Ca2+ influx by Mn2+ and La3+.
Deth, R; Lynch, C, 1981
)
0.26
" However, La3+ potentiated the response of the cell to T3 in respect to calcium accumulation, cAMP concentration, and 2-DG uptake, shifting the dose-response curve of the latter two effects to the left."( An immediate increase in calcium accumulation by rat thymocytes induced by triiodothyronine: its role in the subsequent metabolic responses.
Ingbar, SH; Segal, J, 1984
)
0.27
" With increasing LaCl3 dosage these abnormalities progressively decreased and were completely abolished at the highest dose."( Suppression of experimental atherosclerosis by the Ca++-antagonist lanthanum. Possible role of calcium in atherogenesis.
Apstein, CS; Aspen, AJ; Kramsch, DM, 1980
)
0.5
" In the absence of La3+, the dose-response profile for GABA became biphasic with an appearance of a stimulatory phase at concentrations of GABA lower than 1 microM."( Interaction of La3+ with GABAA receptors in rat cerebrocortical membranes as detected with [35S]t-butylbicyclophosphorothionate binding.
Im, WB; Pregenzer, JF, 1993
)
0.29
" CS contracts the smooth muscle of the aorta in a dose-response relation."( Vasoconstrictor effect of Cissus sicyoides on guinea-pig aortic rings.
Cartas-Heredia, L; García, X; Gijón, E; Lorenzana-Jímenez, M, 1997
)
0.3
" Dose-response studies indicated that Zn2+, Au3+, and Cd2+ depressed binding with half-maximal activities of approximately 20 microM, 14-60 microM, and 50-65 microM, respectively."( Multivalent cations depress ligand binding to cell-associated insulin-like growth factor binding protein-5 on human glioblastoma cells.
McCusker, RH; Sackett, RL, 1998
)
0.3
" Rats were given zinc at a dosage of 2 or 30 mg/kg body wt or glucose by gavage starting 3 days before colitis was induced through the intrarectal administration of dinitro-benzene-sulfonic acid and for 7 days thereafter."( Effect of zinc supplementation on intestinal permeability in experimental colitis.
Barollo, M; D'inca, R; Di Leo, V; Fries, W; Mazzon, E; Sturniolo, GC, 2002
)
0.31
"To study La accumulation and microstructure change of leg bones of rats fed with La(NO(3))(3) in low dosage for a long term."( [La accumulation and microstructure change of leg bones of rats fed with La(NO(3))(3) in low dosage for a long term].
Li, R; Wang, K; Yang, H, 2003
)
0.32
"After the rats were fed by La(NO(3))(3) in dosage of 2 mg x (kg(-1) x d(-1)) for 6 months, the contents of La and Ca,P in the leg bones were determined by ICP MS and spectrophotometry; the microstructure changes of the leg bones were investigated by electron microscopy and X-ray powder diffraction."( [La accumulation and microstructure change of leg bones of rats fed with La(NO(3))(3) in low dosage for a long term].
Li, R; Wang, K; Yang, H, 2003
)
0.32
"La was accumulatied in the rat leg bones and the change of bone microstructure induced after the rats were fed with La(NO(3))(3) in low dosage for a long term."( [La accumulation and microstructure change of leg bones of rats fed with La(NO(3))(3) in low dosage for a long term].
Li, R; Wang, K; Yang, H, 2003
)
0.32
" (2) 40 BALB/c mice were randomly divided into 2 group 2: experimental group injected intraperitoneally with lanthanum chloride of the dosages 10 mg/kg for 3 days and then injected with 1 LD(50) dosage of LPS 30 minutes after the last injection of lanthanum chloride of the dosages 10 mg/kg; and control group injected intraperitoneally with normal saline for 3 days and then with 1 LD(50) dosage of LPS 30 minutes after the last injection of normal saline."( [Anti-endotoxin effect of lanthanum chloride in vivo: an experimental study of mice].
Guo, F; Hu, F; Hu, YY; Wang, Y; Yuan, K, 2004
)
0.84
" Recently, a new medicine, lanthanum carbonate (Fosrenol), has been used to treat chronic renal failure (CRF), and the dosage is much higher than the daily intake of lanthanides."( Neurotoxicological consequence of long-term exposure to lanthanum.
Chai, Z; Feng, L; He, X; Huang, Y; Li, F; Li, Z; Liu, N; Xiao, H; Zhang, Z; Zhao, Y, 2006
)
0.88
" The results obtained indicate that the tested compounds exerted a considerable cytotoxic activity upon the evaluated cell lines in a concentration-dependent matter, which enabled the construction of dose-response curves and the calculation of the corresponding IC(50 )values."( New lanthanum (III) complex--synthesis, characterization, and cytotoxic activity.
Kiefer, W; Kostova, I; Kostovski, A; Rastogi, VK, 2006
)
0.89
" There is no evidence from current studies that it accumulates to biologically significant levels in tissues, but despite the large numbers of patients included in clinical trials, experience with long-term dosing is limited and, as with every new drug used in this type of clinical setting, patients should be carefully monitored as experience with the drug increases."( Lanthanum carbonate.
Freemont, AJ, 2006
)
1.78
" The optimal dosage in Japanese patients needs to be confirmed using a flexible-dose titration schedule."( Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
Shigematsu, T, 2008
)
1.79
" Patients and physicians reported significantly higher levels of satisfaction with reformulated lanthanum carbonate compared with previous phosphate binders, partly because of reduced tablet burden with higher dosage strengths."( Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
Anger, M; Fishbane, S; Martin, KJ; Mehrotra, R; Sprague, SM; Zeig, S, 2008
)
0.91
" Additional rats were dosed intravenously with lanthanum chloride (0."( Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact?
Cox, AG; Damment, SJ; Secker, R, 2009
)
0.83
" These elements in their appropriate dosage range are considered to be beneficial to health."( Analysis of trace elements in Chinese therapeutic foods and herbs.
Xu, H; Xu, HE, 2009
)
0.35
"13microgl(-1) for a worst-case Phoslock dosage of 250mgl(-1)."( Effects of lanthanum and lanthanum-modified clay on growth, survival and reproduction of Daphnia magna.
Lürling, M; Tolman, Y, 2010
)
0.75
" The reasons claimed by patients for their negative ratings of PB were the type of dosage form, the taste, the number of tablets and gastric intolerance."( [Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control].
Álvarez-Ude, F; Arenas, MD; Gil, MT; Malek, T; Moledous, A; Reig-Ferrer, A, 2010
)
0.36
" The main advantages of the nanoparticles tested for routine use were their high colloidal stability allowing a more precise dosage and therefore high reproducibility of DNA isolation."( Silica-coated La0.75Sr0.25MnO3 nanoparticles for magnetically driven DNA isolation.
Kaman, O; Pollert, E; Rittich, B; Spanová, A; Trachtová, S; Veverka, P, 2011
)
0.37
" Feed supplementation for two weeks with approximately 2-20% of this dosage (i."( Tolerability and efficacy of the intestinal phosphate binder Lantharenol® in cats.
Delport, PC; Dribusch, U; Gropp, JM; Schmidt, BH; van der Staay, FJ, 2012
)
0.38
"LC effectively reduced the serum phosphate level (like CaC) and allowed the vitamin D analogue dosage to be increased without hypercalcemia in HD patients."( Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
Chiyotanda, S; Fujimoto, S; Fukudome, K; Kitamura, K; Sato, Y; Toida, T; Yamada, K, 2012
)
0.78
" The mean dosage was increased from initial daily dosage of 744 mg to 1266 mg after 1 year, and to 1246 mg after 2 years."( Multicenter study of long-term (two-year) efficacy of lanthanum carbonate.
Ando, R; Chida, Y; Inoue, A; Ishida, Y; Iwamoto, S; Kikuchi, K; Kimura, H; Ohtsuka, M; Sato, H; Tachibana, K; Takayama, M; Yamada, K; Yoshizaki, Y, 2013
)
0.64
" Patients were given dosage of LA in addition to, or instead of, co-hyperphosphatemia treatments already being received."( Study of prolonged administration of lanthanum carbonate in dialysis patients.
Furui, H; Gotoh, J; Hattori, M; Horie, T; Iida, J; Kawamura, A; Kukita, K; Meguro, J; Onodera, K; Tamaki, T; Tsuchihashi, S; Yonekawa, M, 2013
)
0.66
"To examine the efficacy of long-term administration of lanthanum carbonate, changes in serum Ca, phosphate, whole parathyroid hormone (wPTH), and ALP were examined in 40 patients who were able to tolerate dosage of lanthanum carbonate over a continuous period of 24 months."( Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
Hong, Z; Ishizu, T; Kaneko, Y; Matsunaga, T; Taru, Y, 2013
)
0.9
" The dosage of vitamin D and cinacalcet remained without significant change."( Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.
Ando, R; Chida, Y; Shinoda, T; Suzuki, T; Tagawa, H; Takagi, M; Tanaka, Y; Yamasaki, M, 2013
)
0.61
" The Sev dosage immediately before the switch was 1857 ± 1325 mg/day, and the La dosage 8 weeks after the switch was 821 ± 301 mg/day."( Effects of switch from sevelamer hydrochloride to lanthanum carbonate on serum K and bone metabolic turnover.
Hirose, M; Ishida, Y; Izumiya, Y; Ota, S, 2013
)
0.64
" The general LC dosage form is a chewable pharmaceutical preparation."( Additional reduction in serum phosphorus levels by pulverized lanthanum carbonate chewable in hemodialysis patients.
Kabaya, T; Mitsuhashi, T; Miyajima, S; Nitta, K; Ogawa, T; Ohba, T; Otsuka, K; Shizuku, J; Takahashi, M; Takahashi, N; Yamashita, T, 2013
)
0.63
" Higher LaMZ dosage was found to be favorable for the prevention of ammonium release from the sediments using the ABS."( [Evaluation of in situ capping with lanthanum-modified zeolite to control phosphate and ammonium release from sediments in heavily polluted river].
Li, J; Lin, JW; Zhan, YH, 2013
)
0.66
" In this study, of 22 patients on maintenance dialysis who had been administered calcium (Ca) carbonate in our hospital, we investigated the dosage amount of vitamin D3 preparations after the phosphorus (P) binder was switched from Ca carbonate to the newly developed lanthanum carbonate (LC)."( Increase in the dosage amount of vitamin D3 preparations by switching from calcium carbonate to lanthanum carbonate.
Hida, M; Hyodo, T; Ishii, D; Iwamura, M; Kawakami, J; Kurata, Y; Mikami, N; Wakai, H; Yoshida, K, 2014
)
0.8
"Maintenance dialysis patients at our hospital who had been receiving lanthanum carbonate (LC) chewable tablets were switched to the same dosage of the granules, and the differences in serum phosphorus (P) levels were compared, together with stratifying patients at the baseline characteristics."( Is granular formulation of lanthanum carbonate more effective than chewable tablets?
Haruhara, K; Kamejima, S; Kanzaki, G; Mafune, H; Manabe, M; Mashiko, H; Okamoto, H; Yokoo, T, 2014
)
0.93
" In order to determine the changes that had occurred in the sediments as a result of the addition of the clay, we measured the vertical distribution of lanthanum in the collected cores, calculated La:P ratios of the different sediment layers and used the ratios to determine whether or not the applied dosage was sufficient."( Analysis of the La:P ratio in lake sediments - Vertical and spatial distribution assessed by a multiple-core survey.
Epe, TS; Yasseri, S, 2016
)
0.63
" An inverted-U-shaped dose-response relationship between BC dosage and seed germination/seedling growth can be observed."( Mitigating biochar phytotoxicity via lanthanum (La) participation in pyrolysis.
Deng, S; Hu, Y; Li, Y; Shen, F; Yang, G; Yang, Y; Zeng, Y; Zhang, J; Zhang, Y, 2017
)
0.73
" Dosage of REEs seems to be the pivotal factor for switching the biological effects from down- to up-regulation of cell growth; thus, low concentrations promoted cell survival and proliferation, but when concentrations increased, REEs exerted anti-proliferative and cytostatic/cytotoxic effects."( Effects of the rare elements lanthanum and cerium on the growth of colorectal and hepatic cancer cell lines.
Abete, MC; Benedetto, A; Bocca, C; Brizio, P; Cannito, S; Squadrone, S, 2018
)
0.77
" Batch experiments were performed to evaluate the adsorption capacity at different conditions: pH, temperature, initial concentration, adsorbent dosage and contact time."( Adsorption of phosphorus from slaughterhouse wastewater by carboxymethyl konjac glucomannan loaded with lanthanum.
Chen, Y; He, Y; Lin, X; Luo, X; Zhang, X; Zhou, J, 2018
)
0.7
" In the oral adenine dosing model, serum phosphorus increased markedly and the area under the serum phosphorus concentration-time curve (phosphorus AUC) decreased in a dose-dependent manner with the administration of La formulations."( [Studies of the Various Chronic Kidney Failure Rat Models and Hemodialysis Mini-pig Model for the Evaluation of Anti-hyperphosphatemia Drugs].
Kano, M; Katoh, M; Okabe, T; Okazaki, R; Tanaka, Y; Toyoda, H; Ueno, M, 2019
)
0.51
" However, the over dosage and improper discharge of flutamide could affect the living organism."( Unraveling the electrochemical properties of lanthanum cobaltite decorated halloysite nanotube nanocomposite: An advanced electrocatalyst for determination of flutamide in environmental samples.
Balakrishna, RG; Kokulnathan, T; Suvina, V; Wang, TJ, 2020
)
0.82
" The effects various factors on the adsorption of CTC by La-Z were investigated, including the lanthanum modification concentration on zeolites, the dosage of La-Z, solution pH and reaction time."( Adsorption of chlortetracycline from aquaculture wastewater using modified zeolites.
Liao, J; Tian, S; Xue, B; Yu, R; Yu, X; Zhu, W, 2020
)
0.78
" The optimal conditions for the dye adsorption were found to be pH = 3, initial dye concentration: 50 mg/L and adsorbent dosage of 100 mg."( Synthesis and characterization of La(III) supported carboxymethylcellulose-clay composite for toxic dyes removal: Evaluation of adsorption kinetics, isotherms and thermodynamics.
Karthikeyan, P; Meenakshi, S; Sirajudheen, P; Vigneshwaran, S, 2020
)
0.56
" The results shown that the nitrogen removal efficiency was declines briefly and then gradually recovers after low dosage (1-5 mg/L) La(III) treatment and the decrease to low level (24."( Adaptation, restoration and collapse of anammox process to La(III) stress: Performance, microbial community, metabolic function and network analysis.
Antwi, P; Deng, X; Deng, Y; Lai, C; Liu, Z; Shi, M; Su, H; Xiao, L; Zhang, D; Zhang, Z; Zhao, J, 2021
)
0.62
" The Central Composite Design (CCD), which uses four input variables including dosage (2-5 g/L), solution pH (4-8), contact time (30-70 min), and initial concentration (10-20 mg/L), was used to design the experiments."( Synthesis and application of lanthanum-doped magnetic biochar composite adsorbent for removal of fluoride from water.
Majamo, SL; Teju, MD, 2023
)
1.2
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
scandium group element atom
lanthanoid atom
f-block element atom
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (4,854)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901897 (39.08)18.7374
1990's647 (13.33)18.2507
2000's925 (19.06)29.6817
2010's1085 (22.35)24.3611
2020's300 (6.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.57 (24.57)
Research Supply Index8.54 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index125.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials96 (1.91%)5.53%
Reviews172 (3.43%)6.00%
Case Studies78 (1.56%)4.05%
Observational7 (0.14%)0.25%
Other4,663 (92.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]